With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online ... concerned that there was uncertainty about the mechanism. Cost was also a concern raised by cautious ...

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in US patients hospitalized with heart failure (HF) and a left ventricular ejection fraction > 40% increased substantially within 2 ...

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

Advances in cardiovascular pharmacology have significantly enhanced patient outcomes through a new wave of medications ranging from anticoagulants and antiplatelet agents to lipid-lowering drugs and ...

The challenge for Bayer will be carving out a role for Kerendia in mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) heart failure alongside SGLT2 ... its mechanism of action and ...

For example, the DELIVER trial found that an SGLT2 inhibitor reduced risk of cardiovascular death among patients with heart ...

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

In addition: “SGLT2 inhibitors, unlike thiazolidinediones [a commonly used class of diabetes drugs], have a tendency to increase fluid excretion by a mechanism that depends on osmotic diuresis.

Heart attacks are a leading cause of death and disability in Europe, and their effects often extend beyond the initial event, leading to chronic heart failure.